Veradigm, a healthcare data and technology provider formerly known as Allscripts, has concluded its months-long strategic review without securing a sale or major transaction, the company said Jan. 30.
Despite engaging with more than 30 potential buyers and receiving five nonbinding offers, the company did not receive any final proposals and has decided to move forward independently, according to a press release.
The review, which began in May 2024, explored various options to maximize shareholder value, including a potential acquisition. Veradigm's board of directors, alongside financial and legal advisers, evaluated bids from strategic partners and financial sponsors but ultimately determined that continuing as an independent entity was the best path forward.